Clinical Presentation & Protocol
Patient Usually Complains Of
Patient presents with a chronic, pruritic, erythematous, eczematous-like plaque in the [anogenital/axillary] region. Symptoms include persistent burning, localized pain, and occasional serosanguinous discharge. Lesion has been refractory to topical corticosteroids and antifungal therapies. No history of underlying malignancy or recent trauma.
Clinical Examination Findings
Physical exam reveals a well-demarcated, erythematous, scaly plaque with areas of crusting and excoriation. Lesion margins are irregular. Palpation demonstrates no underlying induration or fixed masses. Regional lymphadenopathy is [absent/present]. Skin integrity is compromised with focal areas of maceration.
Treatment Protocol
Surgical management via wide local excision (WLE) with [2-3 cm] margins to ensure clear histological clearance. Intraoperative frozen section analysis is mandatory. Reconstruction options include primary closure, split-thickness skin graft (STSG), or local rotational flap depending on defect size and anatomical site. Post-operative monitoring for recurrence and secondary infection.
1. Executive Overview: Understanding Extramammary Paget’s Disease
Extramammary Paget’s Disease (EMPD) is a rare, slow-growing intraepidermal adenocarcinoma. It typically presents as a chronic, eczematous-like skin lesion in areas rich in apocrine sweat glands. Unlike classic Paget’s disease of the breast, which is almost always associated with underlying ductal carcinoma, EMPD can be classified as either primary (arising from the epidermis or adnexal structures) or secondary (arising from an underlying internal malignancy, such as rectal or genitourinary carcinoma).
Clinically, it is characterized by persistent erythema, pruritus, and exudation. Due to its deceptive appearance, patients often endure years of misdiagnosis as having chronic dermatitis or fungal infections before a definitive biopsy confirms the diagnosis. Given its potential for recurrence and association with systemic malignancy, a multidisciplinary approach involving dermatologists, surgical oncologists, and plastic surgeons is essential for successful management.
2. Pathophysiology, Etiology, and Risk Factors
The exact pathogenesis of EMPD remains a subject of ongoing research. The hallmark of the disease is the presence of "Paget cells"—large, pale-staining cells with abundant cytoplasm and atypical nuclei—within the epidermis.
Classification of EMPD
- Primary EMPD: Arises within the skin (in situ) from pluripotential cells in the epidermis or adnexal structures. It is generally localized but can become invasive over time.
- Secondary EMPD: Represents the cutaneous extension or metastasis of an underlying visceral malignancy. Common associations include colorectal, bladder, or prostate adenocarcinoma.
Risk Factors
While the etiology is often idiopathic, several risk factors and biological mechanisms are associated with the development of the disease:
* Age and Gender: Most commonly diagnosed in patients between 60 and 80 years of age. It shows a slight female predominance in genital cases, though it affects all genders.
* Apocrine Gland Density: The disease predilects intertriginous areas (anogenital, axillary, and pubic regions) where apocrine sweat glands are most concentrated.
* Genetic Markers: Mutations in the ERBB2 (HER2) gene are frequently identified in EMPD, which has opened doors for targeted molecular therapy in advanced cases.
| Feature | Primary EMPD | Secondary EMPD |
|---|---|---|
| Origin | Intraepidermal/Adnexal | Visceral Malignancy |
| Common Sites | Vulva, Perianal, Scrotum | Rectum, Bladder, Urethra |
| Clinical Course | Localized, slow progression | Reflects underlying malignancy |
| Association | Often isolated | Requires systemic screening |
3. Signs, Symptoms, and Clinical Presentation
EMPD is notoriously "the great mimicker." Patients often report symptoms that have persisted for months or even years.
Common Symptomatology
- Erythema: A well-demarcated, red, scaly patch that may appear eczematous.
- Pruritus: Chronic, intense itching is the most common presenting complaint.
- Exudation: The lesion may become moist, crusted, or ulcerated, leading to secondary bacterial infections.
- Induration: As the disease progresses to an invasive stage, the skin may feel thickened, firm, or nodular.
Anatomic Distribution
The distribution is almost exclusively in areas with apocrine glands:
1. Anogenital (Most common): Vulva, scrotum, penis, and perianal region.
2. Axillary: Less common but clinically significant.
3. Other: Umbilical and eyelid regions (rare).
4. Standard Diagnostic Evaluation & Workup
Early detection is the primary determinant of prognosis. Because the clinical appearance is non-specific, a high index of suspicion is required.
Diagnostic Steps
- Dermatoscopy: Often shows a "white-to-pink" background with irregular, dotted, or globular vascular patterns.
- Punch Biopsy (Gold Standard): Multiple 4mm punch biopsies are required to confirm the diagnosis and distinguish between in situ disease and invasive disease (depth of invasion).
- Histopathology: Confirms the presence of Paget cells (large, clear cells) in the epidermis. Immunohistochemistry (IHC) is vital:
- CK7 (+): Positive in almost all EMPD cases.
- CK20 (+): Suggests secondary EMPD (e.g., associated with colorectal cancer).
- GCDFP-15 (+): Suggests apocrine differentiation.
Systemic Workup
Once a diagnosis of EMPD is confirmed, secondary malignancy must be ruled out, especially for perianal or perigenital lesions:
* Colonoscopy/Sigmoidoscopy: To rule out colorectal malignancy.
* Cystoscopy: To rule out bladder or urethral involvement.
* Imaging: Pelvic MRI or CT scan to evaluate for lymphadenopathy or extension into underlying structures.
5. Therapeutic Interventions
Treatment is tailored based on whether the disease is primary or secondary, and whether it is localized or invasive.
Surgical Management (The Gold Standard)
- Wide Local Excision (WLE): The primary treatment. Because EMPD often exhibits "subclinical spread" (where the tumor extends beyond the visible borders), surgeons often use Mohs Micrographic Surgery (MMS). MMS allows for 100% margin control, which is critical in minimizing recurrence rates in sensitive areas like the genitals.
- Reconstructive Surgery: Following excision, large defects in the perineum or axilla may require split-thickness skin grafts (STSG) or complex rotational flaps, often performed by plastic surgeons to optimize functional and cosmetic outcomes.
Non-Surgical and Adjuvant Therapies
- Topical Imiquimod: Used in select cases of primary, non-invasive (in situ) disease, particularly for elderly patients who are poor surgical candidates.
- Radiation Therapy: Primarily used for palliative purposes or for patients who cannot undergo surgery.
- Targeted Therapy: In metastatic or recurrent disease, HER2-targeted therapies (such as Trastuzumab) have shown promising results in clinical trials.
Long-Term Monitoring
Recurrence is common, often occurring years after initial treatment. Patients require indefinite follow-up, typically every 3–6 months for the first two years, then annually thereafter.
6. Frequently Asked Questions (FAQ)
1. Is Extramammary Paget’s Disease a type of skin cancer?
Yes, it is a rare form of intraepidermal adenocarcinoma, which is a type of skin cancer.
2. Is EMPD contagious?
No, EMPD is not contagious or infectious. It is a malignant growth of skin cells.
3. Why is it often misdiagnosed as eczema?
Both conditions present as red, itchy, and scaly patches. If a "rash" does not respond to topical steroids within 2–4 weeks, a biopsy is mandatory to rule out EMPD.
4. What is the difference between primary and secondary EMPD?
Primary EMPD originates in the skin, while secondary EMPD is a sign of an underlying cancer in an internal organ, like the colon or bladder.
5. Is surgery the only treatment option?
Surgery (specifically Mohs Micrographic Surgery) is the gold standard. However, for patients who cannot have surgery, topical creams (like Imiquimod) or radiation may be considered.
6. Does EMPD spread to other parts of the body?
If left untreated, the disease can progress from "in situ" (contained in the top layer of skin) to invasive, which can then spread to lymph nodes and distant organs.
7. How often does EMPD come back after surgery?
Recurrence rates can be high because the cancer often spreads underneath the skin further than it appears on the surface. This is why surgeons often use wide margins or Mohs surgery.
8. What tests will I need after a diagnosis?
Your doctor will likely order a colonoscopy and cystoscopy to ensure the cancer is not originating from your bowel or bladder.
9. Can EMPD be cured?
If detected early and treated with complete surgical excision, the prognosis is generally good. Long-term surveillance is necessary to ensure no recurrence.
10. What should I look for during self-exams?
Look for persistent redness, itching, or a "weeping" sore in the genital or anal area that does not heal with standard creams. If you notice these, consult a specialist immediately.
Disclaimer: This guide is for educational purposes and does not substitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or qualified health provider with any questions regarding a medical condition.